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INTRODUCTION
The incidence of the residual neuromuscular block-
ade in the recovery room is high (30-50%)1-5 with 
a Train of Four Ratio (TOFR) < 90%.2,6 This condi-
tion can increase morbidity of dyspnea, airway 
obstruction, hypoxia, and the mortality.1,2,7,8
Many trials that prevented residual neuromus-
cular blockade suggest to use a monitoring device 
for neuromuscular blockades and give reversal 
agents for every neuromuscular blocking agent 
administration.5,9,10-12 Practice Guidelines for 
Postanaesthetic Care recommends that neuromus-
cular blockade device is effective to detect neuro-
muscular dysfunction and the administration of 
neostigmine is as effective as residual neuromuscu-
lar blockade antagonist.13 However, the recommen-
dation has not been done routinely, not all of the 
anaesthesiologists use a neuromuscular blockade 
device14 and many anaesthesiologists still depend 
on clinical evaluation for assessing neuromuscular 
block.15,16
Reversal agents are always suggested to be 
given for every neuromuscular blocking agent 
administered by considering the administration 
time and the dose.1,5,9,10-13 The most common rever-
sal agent is neostigmine (0.04-0.07 mg/kgBW).1,17 
A new study suggests giving an adjusted neostigmine 
dose based on the TOFR value postoperative leads 
to complete recovery from neuromuscular blocking 
agent effect with minimal muscarinic effect.1,11,12
Routine administration of reversal has been 
done in Cipto Mangunkusumo General Hospital by 
neostigmine 0.02 mg/kgBW and 0.4 mg of atropine 
sulfate for each 1 mg of neostigmine. However, the 
residual event is still high (43%). This study aims to 
determine the effectiveness of reversal routine dose 
(neostigmine partial dose 0.02 mg/kgBW) in Cipto 
Mangunkusumo General Hospital and adjusted 
dose based on the TOFR value against single dose 
administration of rocuronium 0.6 mg/kgBW.
DESIGN AND METHODS
This was a double-blind randomized clinical 
trial in the Integrated Surgical Care Unit of Cipto 
Mangunkusumo General Hospital and Kirana 
Clinic. Ethical approval from Ethics Committee 
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ABSTRACT
Background: Routine reversal (neostigmine) and the use of 
quantitative monitoring of neuromuscular blockade (Train of Four 
Ratio (TOFR)) are recommended to prevent the occurrence of residual 
paralysis. This study attempted to determine the effectiveness 
between neostigmine partial dose 0.02 mg/kgBW and adjusted dose 
based on TOFR value in recovering neuromuscular blockade of single 
dose rocuronium 0.6 mg/kg BW.
Methods: This randomized clinical trial was performed in the operating 
room of Integrated Surgical Care Unit of Cipto Mangunkusumo General 
Hospital and Kirana Clinic. Sixty-one patients who underwent elective 
surgery with general anaesthesia were randomized into 2 groups: 
administration of neostigmine in partial dose 0.02 mg/kgBW (group 
A) and adjusted dose based on TOFR value (group B). Quantitative 
monitoring evaluation of neuromuscular blockade was performed four 
times: after adequate spontaneous breathing, 5, 10, and 15 minutes 
after reversal.
Result: The mean of TOFR values  in group A and group B respectively: 
after spontaneous breathing, 42% and 50% (p=0.436); 5 minutes 
after reversal, 80.2% and 89.2% (p=0.083); 10 minutes after reversal, 
92.2% and 94% (p=0.399); 15 minutes after reversal, 94.3% and 
94.9% (p=0.526). After the 5 minutes of reversal, group B (80.6%) 
reaches a TOFR value ≥ 90% which is more than group A (63.3%) 
(p=0.132).
Conclusion: Neostigmine partial dose 0.02 mg/kgBW was as effective 
as administering neostigmine in adjustment dose based on TOFR values 
to achieve complete recovery from the neuromuscular block effect 
of single-dose rocuronium 0.6 mg/kg BW. This study also shows the 
complete recovery of the neuromuscular block when TOFR value ≥ 90%.
Keywords: reversal, neostigmine, rocuronium, neuromuscular block, neuromuscular block residual, residual paralysis, partial dose, 
Train-of-Four, TOF value ratio
Cite This Article: Hidayat, J., Marsaban, A.H.M., Ekaputri HD, M.V.T. 2018. Effectiveness of partial and adjustment neostigmine dose as a 
neuromuscular reversal for single dose rocuronium. Bali Journal of Anesthesiology 2(1): 10-16. DOI:10.15562/bjoa.v2i1.62
Effectiveness of partial and adjustment neostigmine 
dose as a neuromuscular reversal for single dose 
rocuronium
Jefferson Hidayat,* Arif HM Marsaban, Maria Veronica Tita Ekaputri HD
11Published by DiscoverSys | Bali Journal of Anesthesiology 2018; 2(1): 10-16 | doi: 10.15562/bjoa.v2i1.62
ORIGINAL ARTICLE
of Faculty Medicine of Universitas Indonesia was 
obtained for this study.
This study utilized a consecutive sampling with 
randomization for all patients who undergo elective 
surgery from November to December 2016. The 
inclusion criteria were patients aged 18-60  years 
old, physical status ASA I-II, planned to undergo 
general anaesthesia for 60-120 minutes, and 
accepted to participate this study. The exclusion 
criteria were patients who had a BMI ≥ 30 kg/ m2, 
severe liver or kidney disease, neuromuscular disor-
der, and asthma. Patients who fulfilled the inclusion 
criteria and did not meet exclusion criteria were 
divided into 2 groups by randomization: patients 
were given neostigmine partial dose 0.02 mg/kgBW 
(Group A) and adjusted dose based on the TOFR 
(Group B). Five patients were removed from this 
study because the duration of surgery was less than 
60 minutes or more than 120 minutes.
After patients arrived in the operation room, 
routine anaesthesia monitoring devices (4 leads 
ECG, pulse oximeter, and noninvasive blood pres-
sure) were attached. Oxygen 100% was given as 
preoxygenation. Midazolam 0.01 mg/kgBW was 
administrated as co-induction. After 1 minute, 
fentanyl 3 μg/kgBW was given. Three minutes after 
fentanyl administration, propofol 1-2 mg/kgBW 
was given for induction. Laryngeal mask airway 
insertion or endotracheal intubation was done with 
rocuronium 0.6 mg/kgBW.
The ventilator was set to pressure controlled 
ventilation or volume controlled ventilation mode, 
targeted tidal volume 6-8 mL/kgBW, respiratory 
rate 12 breaths per minute, I:E ratio 1:2, fresh gas 
flow 1-2 L/min with O2 fraction 30-50% by mix O2 
and compressed air. Sevoflurane 1.2% and fentanyl 
1.2 μg/kgBW/min were given for maintenance 
anaesthesia. Maintenance fluid using crystalloid 
was adjusted to the “4:2:1 Rule”. The temperature 
was monitored during surgery and patient wore a 
blanket to reach normothermia (36-37°C).
When the surgery was done, fentanyl was 
stopped and the patients were observed until 
adequate spontaneous breathing (tidal volume 
≥  5  mL/kgBW) commenced before being evalu-
ated for the TOFR value by TOF-watch. Before the 
reversal agent was administered, the anaesthetic gas 
was stopped, the duration of surgery was noted and 
the TOFR postoperative values were done. 
Neostigmine administration in both groups 
was given with atropine sulfate (0.4 mg per 1mg 
of neostigmine combination). After the reversal 
agent administration, the TOFR was assessed every 
5  minutes until TOFR ≥ 90% before definitive 
airway equipment was removed.
If the reversal agent administration TOFR 
did not reach ≥ 90% after 10 minutes, the second 
reversal would be given. Second reversal dose for 
Group A was same like before, but group B will 
be given adjusted dose based on last TOFR value 
(Table  1). TOFR value evaluation was continued 
every 5  minutes until TOFR ≥ 90% and then the 
definitive airway equipment was removed.
Data analysis was done using SPSS 21.0  software. 
If the data distribution was not normal, the numer-
ical data is presented as a mean ± standard devia-
tion. If the data distribution was normal, the data is 
presented as a mean (minimum value – maximum 
value). The unpaired T-Test or Mann-Whitney 
Test was used to compare two numeric variables. 
Categorical data was presented in n (%) and tested 
by the Chi-square or Fisher test. Results are consid-
ered as statistically significant if p < 0.05. 
RESULTS
There were 945 patients undergoing general anaes-
thesia in the Integrated Surgical Care Unit and 
Kirana Clinic of Cipto Mangunkusumo General 
Hospital. Sixty-six patients fulfilled the inclusion 
criteria and did not have exclusion criteria. Five 
patients were removed because the duration of 
surgery was less than 60 minutes or more than 
120 minutes. The total subjects were divided by 
Table 1  Adjusted dose of neostigmine based on the TOFR value11
Evaluation TOF Action
Quantitative 
(AMG)
TOF count 1 or no 
response
Postpone reversal agent administration 
until TOF count ≥ 2
TOF count 2 atau 3 Give neostigmine 0.05 mg/kgBW. 
Extubate after TOFR achieves 0.9
TOFR < 40% Give neostigmine 0.04 mg/kgBW. 
Extubate after TOFR achieves 0.9
TOFR 40-90% Give neostigmine 0.02 mg/kgBW
TOFR > 90% No reversal agent administration
Table 2  Basic characteristics of subjects
Data
Group A
(Partial dose)
Group B
(Adjusted dose)
Age (year)
Sex (n%)
Male
Female
ASA (n%)
I
II
Body weight (kg)
Height (m)
BMI (kg/m2)
Duration of surgery (minute)
40 (18-60)
20 (66,7)
10 (33,3)
14 (46,7)
16 (53,3)
59 ± 8
161 ± 7
23,02 ± 2,44
80 (60-120)
36 (19-59)
17 (54,8)
14 (45,2)
11 (35,5)
20 (64,5)
61 ± 8
162 ± 8
23,14 ± 2,11
70 (60-120)
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randomization into 2 groups: Group A (30 subjects) 
and Group B (31 subjects).
This study evaluated neuromuscular blockade 
at 5 time intervals: after adequate spontaneous 
breathing in the ending of surgery, at 5 minutes, 
10 minutes, 15 minutes, and 20 minutes after the 
reversal agent administration. All subjects reached 
TOFR ≥ 90% in 15 minutes after reversal agent 
administration thus assessment of the TOFR value 
in 20 minutes after reversal agent administration 
was not done.
Comparison of the TOFR value between Group 
A and Group B can be seen in Table 3. The monitor-
ing of TOFR value did not reach 90% at the end of 
surgery after the patient had adequate breathing. The 
mean of TOFR value in Group A was 42% (2-97%) 
while Group B was 50% (3-100%) (p=0.494). The 
mean TOFR value at 5 minutes after a reversal in 
both groups was almost 90% (Group A (80.2 ± 
22.7%); Group B (89.2 ± 14.8%); p=0.083 based on 
T-test). The mean TOFR value at 10 minutes after a 
reversal in both groups had reached 90% (Group A 
92.2 ± 9.2%; Group B 94.0 ± 6.76%; p=0.399). The 
mean TOFR value at 15 minutes after a reversal in 
both groups had reached ≥ 90% (Group A 94.3 ± 
3.9%; Group B 94.9 ± 3.62%). Both groups were 
analyzed by GLM repeated measurement using 
normalization TOFR value to compare the mean of 
postoperative TOFR and the result was not statisti-
cally different (p=0.253).
Comparison of the time required to reach TOFR 
≥ 90% between Group A and Group B was done by 
comparing the total patients who had reached TOFR 
≥ 90% at every monitored time interval of neuro-
muscular block (Table 4). At 5 minutes after reversal, 
the total subjects in Group B (80.6%; 25  subjects) 
was higher than Group A (63.3%; 19 subjects) with 
p=0.132. At 10 minutes after reversal, subjects of 
both groups that had reached a TOFR value ≥ 90% 
was more than 90% (Group A 93.3%; Group B 
98,8%; p=0.534). All subjects reached TOFR ≥ 90% 
at 15 minutes after the reversal.
Group A and Group B had nearly the same mean 
of total neostigmine dose required to reach TOFR 
≥ 90% (Group A 1.19 (0.96-2.44) mg; Group B 1.3 
(0.3-8.5) mg). However, this difference was not 
statistically significant (p=0.175) (Table 5).
This study had additional data regarding the 
characteristics of reversal agent administration 
in both groups (Table 6). Group B contained 
15  subjects (48.38%) that were given neostigmine 
0.02 mg/kgBW, 5 patients (16.12%) that were not 
given neostigmine because their TOFR was ≥ 90%, 
Table 3  Comparison of the TOFR value between partial dose 
neostigmine and adjusted dose neostigmine
Time
TOFR Value
p value
Group A
(Partial dose)
Group B
(Adjusted dose)
After adequate breathing
5 minutes after reversal
10 minutes after reversal
15 minutes after reversal
42 (2-97)
80.2 ± 22.7
92.2 ± 9.2
94.3 ± 3.9
50 (3-100)
89.2 ± 14.8
94.0 ± 6.76
94.9 ± 3.62
0.436*
0.083†
0.399†
0.526†
* = Mann Whitney Test; † = T Test. Statistical test was done by using transformed data to get 
normal distribution. Data was significant if p<0.05
Table 4  Comparison of time required to reach TOFR ≥ 90% between 
Group A and Group B
Monitoring Time
TOFR 
Value
Group A* Group B*
p ValueN (%) N (%)
After adequate breathing < 90% 26 (86.7%) 26 (83.9%) 0.758†
≥ 90% 4 (13.3%) 5 (16.1%)
5 minutes after reversal < 90% 11 (36.7%) 6 (19.4%) 0.132†
≥ 90% 19 (63.3%) 25 (80.6%)
10 minutes after reversal < 90% 2 (6.7%) 1 (3.2%) 0.534†
≥ 90% 28 (93.3%) 30 (96.8%)
15 minutes after reversal < 90% 0 (0%) 0 (0%)
≥ 90% 30 (100%) 31 (100%)
*= Categorical data presented as n (%);†= Fisher test. Fisher test was done because the 
requirement of Chi square test and T test was not fulfill. Data will be considered as statistically 
significant if p<0.05
Table 5  Comparison of total neostigmine dose required for reach 
TOFR ≥ 90% between Group A and Group B
Neostigmine Dose
Group A
(Partial dose)
Group B
(Adjusted dose)
p 
value
Total neostigmine dose for 
reach TOFR ≥ 90% (mg) 1,19 (0,96-2,44)
* 1,3 (0-3,85)* 0,175†
* =Numerical data with non normal distribution presented as median (minimum-maksimum 
value) † = Mann Whitney Test. Mann Whitney test was done because the requirement of Chi 
square test and T test was not fulfill. Data will be considered as statistically significant if p<0.05
Table 6  Characteristics of first and second reversal agent 
administration
Neostigmine 
dose
Group A
(Partial dose)
Group B
(Adjusted dose)
1st Reversal* 2nd Reversal† 1st Reversal* 2nd Reversal†
Not given - - 5 (16.12%) -
0.02 mg/kgBW 30 2 15 (48.38%) 1
0.04 mg/kgBW - - 10 (32.25%) -
0.05 mg/kgBW - - 1 (3.22%) -
* =after adequate breathing, † = at 10 minutes after first reversal agent administration
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10 patients (32.25%) that were given neostigmine 
0.04 mg/kgBW, and only 1 patient (3.22%) that was 
given neostigmine 0.05 mg/kgBW. A second rever-
sal agent administration at the 10th minute after first 
administration was given to 3 subjects.
DISCUSSION
Complete recovery from neuromuscular block 
postoperative is important because residual neuro-
muscular block may increase morbidity (dyspnea, 
airway obstruction, hypoxia).1,2,7,8 Routine reversal 
agent administration and the usage of quantitative 
monitoring of neuromuscular blockage intraoper-
ative are recommended to prevent residual neuro-
muscular blockage. However, both things were not 
routinely done until now thus the residual case still 
often happens.
A neostigmine therapeutic dose is 0.04 – 0.07 
mg/kgBW while a toxic dose is 0.08 mg/kgBW. 
Neostigmine administration has limitations such 
as muscarinic effect,1,18 recurarization,18 ceiling 
effect,19 no effect for high dose second reversal 
administration (0.07 mg/kgBW)20 and weakness 
of respiratory muscle.18,21 Some adverse effects of 
neostigmine are dose-dependent. New studies aim 
to know the lowest neostigmine dose for recovery 
of neuromuscular block (TOFR 90%) without 
adverse effects.20,22
The distribution of basic characteristics in this 
study is proportionate by age, sex, body weight, 
body mass index, and duration of surgery in both 
groups. Thus, the impact of both groups may be 
considered as the same and there is no need to 
process the controlling of confounding variables.
The duration of surgery in this study was limited 
to 60 – 120 minutes due to the consideration of 
rocuronium pharmacokinetics. Rocuronium 
has a moderate duration of action between 
35-75  minutes.17 However, Debane et. al found 
that the effect of rocuronium is still available until 
120 minutes after single dose administration.9 
Limitation of the duration of surgery intends to 
select only single dose neostigmine without an 
intraoperative intermittent dose. If the patients 
needed to get neuromuscular blocking agents 
intraoperative, neuromuscular blocking agents 
were given but the patients were dropped out of 
this study.
Prolonged duration of action of rocuronium 
can occur because of an interaction with sevoflu-
rane. Sevoflurane increases potency and prolongs 
the duration of action of neuromuscular blocking 
agents, thus the recovery time will be longer.23,25,26 
Interactions between intravenous anaesthetic and 
neuromuscular blocking agents slightly increase 
the potency of neuromuscular blocking agents but 
there is no effect on humans.24 Other factors that 
can prolong the duration of action have been elim-
inated by the inclusion and exclusion criteria.27-36
This study compares TOFR values, duration 
time and total neostigmine dose required to reach 
TOFR ≥ 90% between neostigmine partial dose 
0.02 mg/kgBW (Group A) and adjusted dose based 
on the TOFR (Group B). Neostigmine partial dose 
was considered effective if mean of the TOFR and 
mean of the total neostigmine dose reached TOFR 
≥ 90% while being equal to the adjusted dose.
This study showed that partial dose of neostig-
mine (0.02 mg/kgBW) was as effective as adjusted 
dose based on the TOFR value for reversal of single 
dose rocuronium 0.6 mg/kgBW. This can be seen 
because there is no statistically significance at 
5  minutes and 10 minutes after reversal agent in 
both groups. 
Theoretically, neostigmine adjusted dose based 
on the TOFR as reversal ensures that there is no 
occurrence of residual neuromuscular block post-
operative. A muscarinic side effect of neostigmine 
may be avoided due to the adjustment of the deep 
neuromuscular blockade.11,12,37 The main objective 
of reversal administration is to maximise nicotinic 
transmission by minimising the muscarinic effect.38
The TOFR value can represent how many nico-
tinic receptors in motor end plate bind the neuro-
muscular blocking agents. The TOFR represents 
how deep the neuromuscular blockade is. The 
lower the TOFR value, the deeper the neuromuscu-
lar blockade. Burton et. al found that 70% of recep-
tors must be blocked to avoid muscle contraction.39 
Padmaja et. al showed that TOF count 4 represents 
<70% blocked receptors by neuromuscular block-
ing agents.40 Waud et. al showed that total bound 
receptors in TOF count 4 are 70-75%.41 TOF count 
4 is the best time for reversal administration by 
qualitative evaluation. However, after quantitative 
Figure 1  Schematic of subject selection
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monitoring of neuromuscular blockade was discov-
ered, the reversal is suggested to be given when the 
neuromuscular block is shallow (TOFR 40-60%) by 
neostigmine partial dose (0.02 mg/kgBW) thus the 
muscarinic effect could be avoided.
In this study, neostigmine adjusted dose based 
on the TOFR was not more effective than partial 
dose. Based on the previous study, complete 
recovery of neuromuscular blockade was not only 
influenced by reversal dose but also by the admin-
istration time of the last drug and the degree of 
neuromuscular blockade.22,38 This study found that 
the mean of TOFR at the end of the surgery after 
adequate breathing in both groups was higher than 
40%. The depth of neuromuscular blockade was 
influenced by the rocuronium pharmacokinetics 
itself. Before reversal is given, there is retribution 
and elimination of the neuromuscular block. 
Neuromuscular blocking agents migrate from the 
motor end plate to the central circulation before 
being eliminated from the circulated blood via 
the synaptic cleft.
Group B participants with a TOFR of 40-90% 
after adequate breathing were given  neostigmine 
0.02 mg/kgBW, which was the same dose in 
Group A. This is similar to several previous stud-
ies that showed neostigmine 0.02 mg/kgBW can 
 successfully reach a TOFR ≥ 90%.10,11,20,38
This study compared the duration of time 
required to reach TOFR ≥ 90% between Group A 
and B by assessing the total patients reaching TOFR 
≥ 90% at every neuromuscular blockade. This was 
possible because the TOFR monitoring times in 
this study had been set.
This study showed that total subjects who 
reached TOFR ≥ 90% at 5 minutes after reversal 
administration in Group B was a lot more than in 
Group A (80.6%, 63.3%, respectively). Ten minutes 
after reversal administration, both groups had 
already reached TOFR ≥ 90% (Group A 93.3%, 
Group B 98.8%). However, the differences were 
not statistically significant (p=0.132; p=0.534). All 
subjects in both groups had already reached TOFR 
≥ 90% in 15 minutes after reversal administration. 
This occurred because when reversal was given 
when the degree of neuromuscular block was shal-
low (TOFR 40-60%).
The other data in this study showed that mean 
of the time required to reach TOFR ≥ 90% after 
reversal was 10-15 minutes. This time was not 
much different than the study by Fuchs-Buder 
et. al which showed that the time required was 
10  minutes.20 Likewise, another study by Kajal et. 
al showed that the recovery time of the patient was 
10 minutes after neostigmine 0.01-0.03 mg/kgBW 
with a shallow degree of neuromuscular block at 
the end surgery.22
The total dose of neostigmine to reach 
TOFR ≥ 90% in Group B was higher than Group 
A (Group A 1.19 mg, Group B 1.3 mg). However, 
statistic tests showed that the difference was not 
significant (p=0.175). This result was expected 
because the TOFR value after adequate breathing in 
the end of surgery in Group B had already reached 
40-90%. If this value adjusted to the table of 
adjusted neostigmine dose based on TOFR, Group 
B would  be given neostigmine 0.02 mg/ kgBW 
which was same as Group A.
CONCLUSION
The administration of neostigmine partial dose 
(0.02 mg/kgBW) as a reversal is as effective as 
the administration of neostigmine adjusted dose 
based on the TOFR value for recovery after a 
neuromuscular block by single dose rocuronium 
0.6 mg/ kgBW. There is no statistically significance 
in the time to required to reach TOFR ≥ 90% and 
postoperative TOFR values between a partial dose 
and an adjusted dose of neostigmine.
The total dose of neostigmine to reach 
TOFR  ≥  90% by neostigmine partial dose was 
1.19 mg. The total dose of neostigmine to reach TOFR 
≥ 90% by neostigmine adjusted dose was 1.3 mg.
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